- Home
- LGVN vs CVKD Comparison
LGVN vs CVKD Comparison
Compare LGVN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- CVKD
- Stock Information
- Founded
- LGVN 2014
- CVKD 2022
- Country
- LGVN United States
- CVKD United States
- Employees
- LGVN N/A
- CVKD N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- LGVN Health Care
- CVKD Health Care
- Exchange
- LGVN Nasdaq
- CVKD Nasdaq
- Market Cap
- LGVN 23.4M
- CVKD 29.5M
- IPO Year
- LGVN 2021
- CVKD 2023
- Fundamental
- Price
- LGVN $1.42
- CVKD $12.54
- Analyst Decision
- LGVN Strong Buy
- CVKD Strong Buy
- Analyst Count
- LGVN 3
- CVKD 1
- Target Price
- LGVN $8.67
- CVKD $32.00
- AVG Volume (30 Days)
- LGVN 707.2K
- CVKD 36.2K
- Earning Date
- LGVN 08-13-2025
- CVKD 08-06-2025
- Dividend Yield
- LGVN N/A
- CVKD N/A
- EPS Growth
- LGVN N/A
- CVKD N/A
- EPS
- LGVN N/A
- CVKD N/A
- Revenue
- LGVN $2,225,000.00
- CVKD N/A
- Revenue This Year
- LGVN N/A
- CVKD N/A
- Revenue Next Year
- LGVN $51.48
- CVKD N/A
- P/E Ratio
- LGVN N/A
- CVKD N/A
- Revenue Growth
- LGVN 127.50
- CVKD N/A
- 52 Week Low
- LGVN $1.14
- CVKD $5.70
- 52 Week High
- LGVN $4.88
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- LGVN 54.27
- CVKD 49.98
- Support Level
- LGVN $1.37
- CVKD $11.00
- Resistance Level
- LGVN $1.40
- CVKD $13.56
- Average True Range (ATR)
- LGVN 0.12
- CVKD 1.15
- MACD
- LGVN 0.02
- CVKD 0.25
- Stochastic Oscillator
- LGVN 46.43
- CVKD 80.97
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.